Proteomics approach to illustrate drug action mechanisms

Current Drug Discovery Technologies

Volumn 3, Issue 3, 2006, Pages 199-209

  Wang, Ying ^a   Chiu, Jen Fu ^a   He, Qing Yu ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b JINAN UNIVERSITY   (China)

Author keywords

Drug mechanism; Drug target; Proteomics

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALCOHOL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CALYCULIN A; CISPLATIN; CYANOGINOSIN; CYCLOSPORIN A; DEOXYCHOLIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; INDISULAM; LONAFARNIB; SOMATOMEDIN BINDING PROTEIN 6; THIOACETAMIDE; VINBLASTINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; DRUG MECHANISM; DRUG RESEARCH; DRUG RESISTANCE; GEL ELECTROPHORESIS; HUMAN; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PROTEINS; PROTEOMICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33947231266     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016306780136763     Document Type: Review

References (106)

1. Sun X., Chiu J. F., He Q. Y.: Application of immobilized metal affinity chromatography in proteomics. Expert. Rev. Proteomics 2, 649, (2005).
2. He Q. Y., Chiu J. F.: Proteomics in biomarker discovery and drug development. J. Cell Biochem. 89, 868, (2003).
3. Wang Y., Chiu J. F., He Q. Y.: Proteomics in computer-aided drug design. Curr. Computer-Aided Drug Design 1, 43, (2005).
4. Chow K. U., Nowak D., Kim S. Z., Schneider B., Komor M., Boehrer S., Mitrou P. S., Hoelzer D.: et al. In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling. Pharmacol. Res. 53, 49, (2006).
5. Komori S., Iwata M., Unno T., Ohashi H.: Modulation of carbachol-induced [Ca2+]i oscillations by Ca2+ influx in single intestinal smooth muscle cells. Br. J. Pharmacol. 119, 245, (1996).
6. Jungblut P., Baumeister H., Klose J. Classification of mouse liver proteins by immobilized metal affinity chromatography and two-dimensional electrophoresis. Electrophoresis 14, 638, (1993).
7. Lei Q. P., Cui X., Kurtz D. M., Jr., Amster I. J., Chernushevich I. V., Standing K. G. Electrospray mass spectrometry studies of non-heme iron-containing proteins. Anal. Chem. 70, 1838, (1998).
8. Zhang J., McCombie G., Guenat C., Knochenmuss R.: FT-ICR mass spectrometry in the drug discovery process. Drug Discov. Today 10, 635, (2005).
9. Wang T., Gu S., Ronni T., Du Y. C., Chen X.: In vivo dual-tagging proteomic approach in studying signaling pathways in immune response. J. Proteome. Res. 4, 941, (2005).
10. Chi S. W., Ayed A., Arrowsmith C. H.: Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. EMBO J. 18, 4438, (1999).
11. Wang Y., He Q. Y., Sun R. W., Che C. M., Chiu J. F.: Gold(III) porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res. 65, 11553, (2005).
12. Wang Y., He Q. Y., Che C. M., Chiu J. F.: Proteomic characterization of the cytotoxic mechanism of gold (III) porphyrin 1a, a potential anticancer drug. Proteomics 6, 131, (2006).
13. Lau A. T., He Q. Y., Chiu J. F.: A proteome analysis of the arsenite response in cultured lung cells: evidence for in vitro oxidative stress-induced apoptosis. Biochem. J. 382, 641, (2004).
14. Schlosser G., Vekey K., Malorni A., Pocsfalvi G.: Combination of solid-phase affinity capture on magnetic beads and mass spectrometry to study non-covalent interactions: example of minor groove binding drugs. Rapid Commun. Mass Spectrom. 19, 3307, (2005).
15. Hemers E., Duval C., McCaig C., Handley M., Dockray G. J., Varro A. Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: implications for epithelial-mesenchymal signaling. Cancer Res. 65, 7363, (2005).
16. Malatos S., Neubert H., Kicman A. T., Iles R. K.: Identification of placental transforming growth factor-beta and bikunin metabolites as contaminants of pharmaceutical human chorionic gonadotrophin preparations by proteomic techniques. Mol. Cell Proteomics 4, 984, (2005).
17. Levchenko A., Mehta B. M., Niu X., Kang G., Villafania L., Way D., Polycarpe D., Sadelain M. et al.: Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc. Natl. Acad. Sci. USA 102, 1933, (2005).
18. Fu Z., Fenselau C.: Proteomic evidence for roles for nucleolin and poly[ADP-ribosyl] transferase in drug resistance. J. Proteome. Res. 4, 1583, (2005).
19. Godl K., Gruss O. J., Eickhoff J., Wissing J., Blencke S., Weber M., Degen H., Brehmer D.: et al. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res. 65, 6919, (2005).
20. Ren H., Tai S. K., Khuri F., Chu Z., Mao L.: Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells. Cancer Res. 65, 5841, (2005).
21. Miura Y., Kano M., Abe K., Urano S., Suzuki S., Toda T.: Age-dependent variations of cell response to oxidative stress: proteomic approach to protein expression and phosphorylation. Electrophoresis 26, 2786, (2005).
22. Zheng H., Hu P., Quinn D. F., Wang Y. K.: Phosphotyrosine proteomic study of interferon alpha signaling pathway using a combination of immunoprecipitation and immobilized metal affinity chromatography. Mol. Cell Proteomics 4, 721, (2005).
23. Sjoholt G., Anensen N., Wergeland L., Mc C. E., Bruserud O., Gjertsen B. T.: Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Curr. Drug Targets. 6, 631, (2005).
24. Papoian R., Scherer A., Saulnier M., Staedtler F., Cordier A., Legay F., Maurer G., Staeheli J.: et al. VeloceGenomics: an accelerated in vivo drug discovery approach to rapidly predict the biologic, drug-like activity of compounds, proteins, or genes. Pharm. Res. 22, 1597, (2005).
25. Huang J., Zhu H., Haggarty S. J., Spring D. R., Hwang H., Jin F., Snyder M., Schreiber S. L.: Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc. Natl. Acad. Sci. USA 101, 16594, (2004).
26. Gail R., Frank R., Wittinghofer A.: Systematic peptide array-based delineation of the differential beta-catenin interaction with Tcf4, E-cadherin, and adeno-matous polyposis coli. J. Biol. Chem. 280, 7107, (2005).
27. Lee H. T., Lee J. G., Na M., Kay E. P.: FGF-2 induced by interleukin-1 beta through the action of phosphatidylinositol 3-kinase mediates endothelial mesenchymal transformation in corneal endothelial cells. J. Biol. Chem. 279, 32325, (2004).
28. Kim K., Cho S., Park J. H., Byun Y., Chung H., Kwon I. C., Jeong S. Y.: Surface plasmon resonance studies of the direct interaction between a drug/intestinal brush border membrane. Pharm. Res. 21, 1233, (2004).
29. Wulfkuhle J., Espina V., Liotta L., Petricoin E.: Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur. J. Cancer 40, 2623, (2004).
30. Svensson S., Jirstrom K., Ryden L., Roos G., Emdin S., Ostrowski M. C., Landberg G.: ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24, 4370, (2005).
31. Neal R., Aykin-Burns N., Ercal N., Zigler J. S., Jr.: Pb2+ exposure alters the lens alpha A-crystallin protein profile in vivo and induces cataract formation in lens organ culture. Toxicology 212, 1, (2005).
32. Tantivejkul K., Loberg R. D., Mawocha S. C., Day L. L., John L. S., Pienta B. A., Rubin M. A., Pienta K. J.: PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J. Cell Biochem. 96, 641, (2005).
33. Cho S. Y., Polster J., Engles J. M., Hilton J., Abraham E. H., Wahl R. L.: In vitro evaluation of adenosine 5'-monophosphate as an imaging agent of tumor metabolism. J. Nucl. Med. 47, 837, (2006).
34. Hoffert J. D., Pisitkun T., Wang G., Shen R. F., Knepper M. A.: Quantitative phosphoproteomics of vasopressin-sensitive renal cells: Regulation of aquaporin-2 phosphorylation at two sites. Proc. Natl. Acad. Sci. USA 103, 7159, (2006).
35. Mayya V., Rezaul K., Wu L., Fong M. B., Han D. K.: Absolute quantification of multi-site phosphorylation by selective reaction monitoring mass spectrometry: Determination of inhibitory phosphorylation status of cyclin dependent kinases. Mol. Cell Proteomics 5, 1146, (2006).
36. D'Astous M., Mendez P., Morissette M., Garcia-Segura L. M., Di Paolo T.: Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Mol. Pharmacol. 69, 1492, (2006).
37. Czupalla C., Mansukoski H., Riedl T., Thiel D., Krause E., Hoflack B.: Proteomic analysis of lysosomal acid hydrolases secreted by osteoclasts: implications for lytic enzyme transport and bone metabolism. Mol. Cell Proteomics 5, 134, (2006).
38. Wu S. L., Kim J., Hancock W. S., Karger B.: Extended Range Proteomic Analysis (ERPA): a new and sensitive LC-MS platform for high sequence coverage of complex proteins with extensive post-translational modifications- comprehensive analysis of beta-casein and epidermal growth factor receptor (EGFR). J. Proteome. Res. 4, 1155, (2005).
39. Tam E. M., Morrison C. J., Wu Y. I., Stack M. S., Overall C. M.: Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc. Natl. Acad. Sci. USA 101, 6917, (2004).
40. Oda Y., Owa T., Sato T., Boucher B., Daniels S., Yamanaka H., Shinohara Y., Yokoi A. et al.: Quantitative chemical proteomics for identifying candidate drug targets. Anal. Chem. 75, 2159, (2003).
41. Ballell L., Alink K. J., Slijper M., Versluis C., Liskamp R. M., Pieters R. J.: A new chemical probe for proteomics of carbohydrate-binding proteins. Chembiochem 6, 291, (2005).
42. Godl K., Wissing J., Kurtenbach A., Habenberger P., Blencke S., Gutbrod H., Salassidis K., Stein-Gerlach M. et al.: An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. USA 100, 15434, (2003).
43. Leung D., Hardouin C., Boger D. L., Cravatt B. F.: Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotechnol. 21, 687, (2003).
44. Bock J. R., Gough D. A.: A new method to estimate ligand-receptor energetics. Mol. Cell Proteomics 1, 904, (2002).
45. Tian Q., Feetham M. C., Tao W. A., He X. C., Li L., Aebersold R., Hood L.: Proteomic analysis identifies that 14-3-3zeta interacts with beta-catenin and facilitates its activation by Akt. Proc. Natl. Acad. Sci. USA 101, 15370, (2004).
46. Astoul E., Laurence A. D., Totty N., Beer S., Alexander D. R., Cantrell D. A.: Approaches to define antigen receptor-induced serine kinase signal transduction pathways. J. Biol. Chem. 278, 9267, (2003).
47. MacKeigan J. P., Clements C. M., Lich J. D., Pope R. M., Hod Y., Ting J. P.: Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res. 63, 6928, (2003).
48. Stoughton R. B., Friend S. H.: How molecular profiling could revolutionize drug discovery. Nat. Rev. Drug Discov. 4, 345, (2005).
49. Smith C.: Drug target identification: a question of biology. Nature 428, 225, (2004).
50. Davies A. R., Belsey M. J., Kozlowski R. Z.: Volume-sensitive organic osmolyte/anion channels in cancer: novel approaches to studying channel modulation employing proteomics technologies. Ann. N. Y. Acad. Sci. 1028, 38, (2004).
51. Laragione T., Bonetto V., Casoni F., Massignan T., Bianchi G., Gianazza E., Ghezzi P.: Redox regulation of surface protein thiols: identification of integrin alpha-4 as a molecular target by using redox proteomics. Proc. Natl. Acad. Sci. USA 100, 14737, (2003).
52. Zhou S., Chan E., Duan W., Huang M., Chen Y. Z.: Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 37, 41, (2005).
53. Low T. Y., Leow C. K., Salto-Tellez M., Chung M. C.: A proteomic analysis of thioacetamide-induced hepa-totoxicity and cirrhosis in rat livers. Proteomics 4, 3960, (2004).
54. Venkatraman A., Landar A., Davis A. J., Chamlee L., Sanderson T., Kim H., Page G., Pompilius M. et al.: Modification of the mitochondrial proteome in response to the stress of ethanol-dependent hepatotoxicity. J. Biol. Chem. 279, 22092, (2004).
55. Steiner S., Aicher L., Raymackers J., Meheus L., Esquer-Blasco R., Anderson N. L., Cordier A.: Cyclosporine A decreases the protein level of the calcium-binding protein calbindin-D 28kDa in rat kidney. Biochem. Pharmacol. 51, 253, (1996).
56. Aicher L., Wahl D., Arce A., Grenet O., Steiner S.: New insights into cyclosporine A nephrotoxicity by proteome analysis. Electrophoresis 19, 1998, (1998).
57. Wang Y., Cheung Y. H., Yang Z., Chiu J. F., Che C. M., He Q. Y.: Proteomic approach to study the cytotoxicity of dioscin (saponin). Proteomics 6, 2422, (2006).
58. Xie L., Tsaprailis G., Chen Q. M.: Proteomic identification of insulin-like growth factor-binding protein-6 induced by sublethal H2O2 stress from human diploid fibroblasts. Mol. Cell Proteomics 4, 1273, (2005).
59. Kanski J., Hong S. J., Schoneich C.: Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine- containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J. Biol. Chem. 280, 24261, (2005).
60. Kopec K. K., Bozyczko-Coyne D., Williams M.: Target identification and validation in drug discovery: the role of proteomics. Biochem. Pharmacol. 69, 1133, (2005).
61. Vaux D. L., Korsmeyer S. J.: Cell death in development. Cell 96, 245, (1999).
62. Nawrocki S. T., Carew J. S., Pino M. S., Highshaw R. A., Dunner K., Jr., Huang P., Abbruzzese J. L., McConkey D. J.: Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 65, 11658, (2005).
63. O'Neill E., Rushworth L., Baccarini M., Kolch W.: Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306, 2267, (2004).
64. Brehmer D., Greff Z., Godl K., Blencke S., Kurtenbach A., Weber M., Muller S., Klebl B. et al.: Cellular targets of gefitinib. Cancer Res. 65, 379, (2005).
65. Sitek B., Apostolov O., Stuhler K., Pfeiffer K., Meyer H. E., Eggert A., Schramm A.: Identification of dynamic proteome changes upon ligand activation of Trk-receptors using two-dimensional fluorescence difference gel electrophoresis and mass spectrometry. Mol. Cell Proteomics 4, 291, (2005).
66. Shiio Y., Suh K. S., Lee H., Yuspa S. H., Eisenman R. N., Aebersold R.: Quantitative proteomic analysis of myc-induced apoptosis: a direct role for Myc induction of the mitochondrial chloride ion channel, mtCLIC/CLIC4. J. Biol. Chem. 281, 2750, (2006).
67. Reyzer M. L., Caldwell R. L., Dugger T. C., Forbes J. T., Ritter C. A., Guix M., Arteaga C. L., Caprioli R. M.: Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res. 64, 9093, (2004).
68. Li N., Guo R., Li W., Shao J., Li S., Zhao K., Chen X., Xu N. et al.: A proteomic investigation into a human gastric cancer cell line BGC823 treated with diallyl trisulfide. Carcinogenesis, 27, 1222, (2006).
69. Yim E. K., Lee K. H., Bae J. S., Namkoong S. E., Um S. J., Park J. S.: Proteomic analysis of antiproliferative effects by treatment of 5-fluorouracil in cervical cancer cells. DNA Cell Biol. 23, 769, (2004).
70. Gu S., Du Y., Chen J., Liu Z., Bradbury E. M., Hu C. A., Chen X.: Large-scale quantitative proteomic study of PUMA-induced apoptosis using two-dimensional liquid chromatography-mass spectrometry coupled with amino acid-coded mass tagging. J. Proteome. Res. 3, 1191, (2004).
71. Skalnikova H., Halada P., Dzubak P., Hajduch M., Kovarova H.: Protein fingerprints of anti-cancer effects of cyclin-dependent kinase inhibition: identiication of candidate biomarkers using 2-D liquid phase separation coupled to mass spectrometry. Technol. Cancer Res. Treat. 4, 447, (2005).
72. Chen T., Wang Q., Cui J., Yang W., Shi Q., Hua Z., Ji J., Shen P.: Induction of apoptosis in mouse liver by microcystin-LR: a combined transcriptomic, proteomic, and simulation strategy. Mol. Cell Proteomics 4, 958, (2005).
73. Yan Y., Weaver V. M., Blair I. A.: Analysis of protein expression during oxidative stress in breast epithelial cells using a stable isotope labeled proteome internal standard. J. Proteome. Res. 4, 2007, (2005).
74. Niture S. K., Doneanu C. E., Velu C. S., Bailey N. I., Srivenugopal K. S.: Proteomic analysis of human O6-methylguanine-DNA methyltransferase by affinity chromatography and tandem mass spectrometry. Biochem. Biophys. Res. Commun. 337, 1176, (2005).
75. Keezer S. M., Ivie S. E., Krutzsch H. C., Tandle A., Libutti S. K., Roberts D. D.: Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res. 63, 6405, (2003).
76. Wissing J., Godl K., Brehmer D., Blencke S., Weber M., Habenberger P., Stein-Gerlach M., Missio A.: et al. Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. Mol. Cell Proteomics 3, 1181, (2004).
77. Dasgupta B., Yi Y., Hegedus B., Weber J. D., Gutmann D. H.: Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine amino-peptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma. Cancer Res. 65, 9843, (2005).
78. Bohman S., Matsumoto T., Suh K., Dimberg A., Jakobsson L., Yuspa S., Claesson-Welsh L.: Proteomic Analysis of Vascular Endothelial Growth Factor-induced Endothelial Cell Differentiation Reveals a Role for Chloride Intracellular Channel 4 (CLIC4) in Tubular Morphogenesis. J. Biol. Chem. 280, 42397, (2005).
79. Karsan A., Pollet I., Yu L. R., Chan K. C., Conrads T. P., Lucas D. A., Andersen R., Veenstra T.: Quantitative proteomic analysis of sokotrasterol sulfate-stimulated primary human endothelial cells. Mol. Cell Proteomics 4, 191, (2005).
80. Longley D. B., Johnston P. G.: Molecular mechanisms of drug resistance. J. Pathol. 205, 275, (2005).
81. Castagna A., Antonioli P., Astner H., Hamdan M., Righetti S. C., Perego P., Zunino F., Righetti P. G.: A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 4, 3246, (2004).
82. Bernstein H., Payne C. M., Kunke K., Crowley-Weber C. L., Waltmire C. N., Dvorakova K., Holubec H., Bernstein C. et al.: A proteomic study of resistance to deoxycholate-induced apoptosis. Carcinogenesis 25, 681, (2004).
83. Verrills N. M., Walsh B. J., Cobon G. S., Hains P. G., Kavallaris M.: Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J. Biol. Chem. 278, 45082, (2003).
84. Jordan M. A., Wilson L.: Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 10, 123, (1998).
85. Yamazaki Y., Tsuruga M., Zhou D., Fujita Y., Shang X., Dang Y., Kawasaki K., Oka S.: Cytoskeletal disruption accelerates caspase-3 activation and alters the intracellular membrane reorganization in DNA damage-induced apoptosis. Exp. Cell Res. 259, 64, (2000).
86. Kulms D., Dussmann H., Poppelmann B., Stander S., Schwarz A., Schwarz T.: Apoptosis induced by disruption of the actin cytoskeleton is mediated via activation of CD95 (Fas/APO-1). Cell Death. Differ. 9, 598, (2002).
87. Gottesman M. M.: Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615, (2002).
88. Hutter G., Sinha P.: Proteomics for studying cancer cells and the development of chemoresistance. Proteomics 1, 1233, (2001).
89. Docquier F., Farrar D., D'Arcy V., Chernukhin I., Robinson A. F., Loukinov D., Vatolin S., Pack S. et al.: Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis. Cancer Res. 65, 5112, (2005).
90. Shin Y. K., Yoo B. C., Chang H. J., Jeon E., Hong S. H., Jung M. S., Lim S. J., Park J. G.: Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res. 65, 3162, (2005).
91. Morand J. P., Macri J., Adeli K.: Proteomic profiling of hepatic endoplasmic reticulum-associated proteins in an animal model of insulin resistance and metabolic dyslipidemia. J. Biol. Chem. 280, 17626, (2005).
92. Coldham N. G., Woodward M. J.: Characterization of the Salmonella typhimurium proteome by semi-automated two dimensional HPLC-mass spectrometry: detection of proteins implicated in multiple antibiotic resistance. J. Proteome. Res. 3, 595, (2004).
93. Drummelsmith J., Girard I., Trudel N., Ouellette M.: Differential protein expression analysis of Leishmania major reveals novel roles for methionine adenosyltransferase and S-adenosylmethionine in methotrexate resistance. J. Biol. Chem. 279, 33273, (2004).
94. Chen C. Y., Jia J. H., Zhang M. X., Meng Y. S., Kong D. X., Pan X. L., Yu X. P.: Proteomic analysis on multi-drug resistant cells HL-60/DOX of acute myeloblastic leukemia. Chin J. Physiol. 48, 115, (2005).
95. Huber M., Bahr I., Kratzschmar J. R., Becker A., Muller E. C., Donner P., Pohlenz H. D., Schneider M. R. et al.: Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen- resistant derivative T47D-r. Mol. Cell Proteomics 3, 43, (2004).
96. Zheng P. Z., Wang K. K., Zhang Q. Y., Huang Q. H., Du Y. Z., Zhang Q. H., Xiao D. K., Shen S. H. et al.: Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/ apoptosis of promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 102, 7653, (2005).
97. Shu H., Chen S., Bi Q., Mumby M., Brekken D. L.: Identification of phosphoproteins and their phosphorylation sites in the WEHI-231 B lymphoma cell line. Mol. Cell Proteomics 3, 279, (2004).
98. Fu W. Y., Xu L. H., Yu Y. N.: Proteomic analysis of cellular response to microcystin in human amnion FL cells. J. Proteome. Res. 4, 2207, (2005).
99. Huang D., Liu X., Plymate S. R., Idowu M., Grimes M., Best A. M., McKinney J. L., Ware J. L.: Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12. Oncogene 23, 6881, (2004).
100. Fam S. R., Paquet M., Castleberry A. M., Oller H., Lee C. J., Traynelis S. F., Smith Y., Yun C. C. et al.: P2Y1 receptor signaling is controlled by interaction with the PDZ scaffold NHERF-2. Proc. Natl. Acad. Sci. USA 102, 8042, (2005).
101. Marta C. B., Montano M. B., Taylor C. M., Taylor A. L., Bansal R., Pfeiffer S. E.: Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis. J. Biol. Chem. 280, 8985, (2005).
102. Ueda K., Kosako H., Fukui Y., Hattori S.: Proteomic identification of Bcl2-associated athanogene 2 as a novel MAPK-activated protein kinase 2 substrate. J. Biol. Chem. 279, 41815, (2004).
103. Feilner T., Hultschig C., Lee J., Meyer S., Immink R. G., Koenig A., Possling A., Seitz H. et al.: High Throughput Identification of Potential Arabidopsis Mitogen-activated Protein Kinases Substrates. Mol. Cell Proteomics 4, 1558, (2005).
104. Blagoev B., Kratchmarova I., Ong S. E., Nielsen M., Foster L. J., Mann M.: A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat. Biotechnol. 21, 315, (2003).
105. Lin Z., Crockett D. K., Jenson S. D., Lim M. S., Elenitoba-Johnson K. S.: Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells. Mol. Cell Proteomics 3, 820, (2004).
106. Collins M. O., Yu L., Coba M. P., Husi H., Campuzano I., Blackstock W. P., Choudhary J. S., Grant S. G.: Proteomic analysis of in vivo phosphorylated synaptic proteins. J. Biol. Chem. 280, 5972, (2005).